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Abstract
Background: To evaluate health-related quality of life (HRQL) and medication satisfaction after switching from a stable dose
of oral extended-release methylphenidate (ER-MPH) to methylphenidate transdermal system (MTS) via a dose-transition
schedule in children with attention-deficit/hyperactivity disorder (ADHD).
Methods: In a 4-week, multisite, open-label study, 171 children (164 in the intent-to-treat [ITT] population) aged 6-12 years
diagnosed with ADHD abruptly switched from a stable dose of oral ER-MPH to MTS nominal dosages of 10, 15, 20, and 30 mg
using a predefined dose-transition schedule. Subjects remained on the scheduled dose for the first week, after which the dose
was then titrated to an optimal effect. The ADHD Impact Module-Children (AIM-C), a disease-specific validated HRQL survey
instrument measuring child and family impact, was used to assess the impact of ADHD symptoms on the lives of children and
their families at baseline and study endpoint. Satisfaction with MTS use was assessed via a Medication Satisfaction Survey (MSS)
at study endpoint. Both the AIM-C and MSS were completed by a caregiver (parent/legally authorized representative).
Tolerability was monitored by spontaneous adverse event (AE) reporting.
Results: AIM-C child and family HRQL mean scores were above the median possible score at baseline and were further
improved at endpoint across all MTS doses. Similar improvements were noted for behavior, missed doses, worry, and economic
impact AIM-C item scores. Overall, 93.8% of caregivers indicated a high level of satisfaction with their child's use of the study
medication. The majority of treatment-emergent AEs (> 98%) were mild to moderate in intensity, and the most commonly
reported AEs included headache, decreased appetite, insomnia, and abdominal pain. Seven subjects discontinued the study due
to intolerable AEs (n = 3) and application site reactions (n = 4).
Conclusion: This study demonstrates that MTS, when carefully titrated to optimal dose, may further improve child and family
HRQL, as well as behavioral, medication worry, and economic impact item scores, as measured by the AIM-C in subjects
switching to MTS from a stable dose of routinely prescribed oral ER-MPH after a short treatment period. Furthermore, following
the abrupt conversion from oral ER-MPH to MTS, the majority of caregivers reported being highly satisfied with MTS as a
treatment option for their children with ADHD.
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Attention-deficit/hyperactivity disorder (ADHD) is a com-
mon psychiatric disorder of childhood, affecting an esti-
mated 7-10% of school-aged children [1-3] and often
persists into adolescence and even adulthood [4-7].
Beyond a greater risk for developing mental health comor-
bidities such as mood and substance use disorders [8-11],
children with ADHD struggle with impairment in aca-
demic functioning, self-esteem, and interpersonal rela-
tionships [12,13]. Families of children with ADHD
frequently experience considerable emotional and finan-
cial stressors [14,15]. These harmful effects of ADHD on
patients and families make it a public health concern and
affirm the need for effective treatment [16].
Psychostimulants are recognized as one of the first-line
treatments for children with ADHD [1,3,13,17], and
methylphenidate (MPH) has been established as an effec-
tive agent in reducing ADHD symptoms [18,19]. Accord-
ingly, oral MPH formulations are frequently prescribed
medications for this disorder [20]. The methylphenidate
transdermal system (MTS; Daytrana® [Shire Pharmaceuti-
cals Ireland Ltd., Dublin, Ireland]), an alternative to oral
MPH formulation, is approved by the US Food and Drug
Administration (FDA) as part of a comprehensive treat-
ment for ADHD in children aged 6-12 years [21]. MTS is
a diffusion-based patch, using DOT Matrix® technology
(Noven Pharmaceuticals, Miami, FL), that continuously
delivers racemic MPH when applied to intact skin [22].
The dose of drug delivered depends on the surface area of
the patch and the length of time that the patch is worn,
which allows for tailoring the duration of medication
effect with reductions of first-pass metabolism and fluctu-
ating plasma concentrations encountered with oral medi-
cations [23,24]. The efficacy and tolerability of MTS have
been demonstrated in several clinical studies of school-
aged children [25-28].
ADHD treatments, such as MTS, can lead to reduced fre-
quency or severity of symptoms; however, these treat-
ments may not directly translate to improvements in the
patient's health-related quality of life (HRQL) at home, at
school, or with peers. The behavior rating scales com-
monly used to assess efficacy are not specifically designed
to evaluate the effect of treatment on the everyday lives of
children and families living with ADHD. In recent years,
the development of multidimensional HRQL question-
naires has afforded clinicians the opportunity to measure
the health of children with ADHD more comprehensively
[29-37]. Subsequently, a number of reports have been
published regarding the improvement of HRQL for chil-
dren with ADHD receiving pharmacotherapy, primarily
atomoxetine, a nonstimulant medication approved by the
FDA for the treatment of ADHD [38-46]. To date, there are
no published data documenting changes in HRQL after
subjects switch from oral ER-MPH to MTS. The purpose of
this research was to examine whether changes in HRQL
and medication satisfaction occur after switching from a
stable oral ER-MPH dose to a carefully titrated, optimized
dose of MTS after 4 weeks of treatment.
Subjects and Methods
Subjects
Children aged 6-12 years, with a confirmed diagnosed of
ADHD (any subtype) by the Diagnostic and Statistical Man-
ual of Mental Disorders Fourth Edition, Text Revision (DSM-
IV-TR®, [American Psychiatric Publishing, Inc., Arlington,
VA]), and whose parent/legally authorized representative
(hereafter referred to as caregiver) was considering a
change in treatment based on efficacy, tolerability, or
compliance were eligible to participate in the study. Sub-
jects were required to have their ADHD symptoms ade-
quately controlled on a stable dose of oral ER-MPH
(Ritalin LA® [Novartis AG, Basel, Switzerland], Concerta®
[Alza Corporation, Palo Alto, CA], or Metadate CD® [UCB
Inc., Atlanta, GA] not to exceed 54 mg/day) for at least 30
days prior to screening. At baseline, subjects were required
to have a total score of ≤ 1.5 standard deviations (SDs)
from age-appropriate norms on the ADHD-Rating Scale-
IV (ADHD-RS-IV) [27], normal laboratory parameters,
vital signs, electrocardiogram (ECG), and a body mass
index (BMI) not exceeding the 90th percentile.
Based on medical history collected at screening, children
were excluded from study enrollment if they had any
comorbid psychiatric diagnosis (with the exception of
oppositional defiant disorder), mental retardation, or any
concurrent illness or skin disorder that might compro-
mise safety or study assessments. Subjects could not have
taken clonidine, atomoxetine, antidepressants, antihyper-
tensives, medications with central nervous system effects,
sedatives, antipsychotics, anxiolytics, anticonvulsants, or
other investigational medications within 30 days prior to
screening.
Data were collected at 18 sites across the United States; the
Institutional Review Board at each site or a central Institu-
tional Review Board approved the study. The subject
agreed to the study and the subject's caregiver provided
written consent in accordance with the International Con-
ference on Harmonisation Good Clinical Practice Guide-
line E6 and applicable regulations.
Study design
This was a prospective, open-label, multicenter study of
MTS primarily designed to evaluate effectiveness and tol-
erability after abrupt conversion from ER-MPH to MTS
[47]; however, important secondary objectives, HRQL
and medication satisfaction, were also evaluated and are
the primary focus of this report.Page 2 of 12
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baseline/MTS initiation, MTS adjustment, and MTS main-
tenance (Figure 1). In addition, a follow-up phone call
was made to caregivers 30 days following the last dose of
study drug to access any additional or ongoing adverse
events (AEs).
Subjects entered the screening period on their existing
dose of oral ER-MPH and continued that medication until
the baseline visit at which time they were switched to MTS
using a predefined dose-transition schedule (Table 1).
Patches were to be applied to alternating hips once daily
in the morning and worn for up to 9 hours each day. Sub-
jects remained on their initial MTS transition dose for 1
week and then entered a 2-week dose-adjustment period.
Titration to a higher dose or tapering to a lower dose of
MTS was permitted based on tolerability and scores on the
Clinical Global Impression-Severity (CGI-S) scale. For
titration purposes, response to MTS was categorized by
the investigator into 1 of 4 conditions and associated
actions: "Intolerable" (unacceptable safety profile); "Inef-
fective" (if the subject's CGI-S score had become worse
compared with baseline, or the subject had a CGI-S score
of 4 [moderately ill] or worse); "Acceptable" (similar or
better ADHD symptom control compared with the base-
line ADHD-RS-IV score, with minimal side effects and
CGI-S score of 3 [mildly ill] or better); or "Optimal", indi-
cating superior ADHD symptom control (CGI-S score of 2
[borderline mentally ill] or 1 [not ill at all, normal]).
"Intolerable" responses required the subject to be tapered
to a lower dose, if available. "Ineffective" responses
required increasing the subject's MTS dose to the next
available strength if side effects permitted. "Acceptable"
responses permitted the subject to be maintained on the
current dose for the remainder of the dose-optimization
MTS abrupt conversion study designFigure 1
MTS abrupt conversion study design. MTS = methylphenidate transdermal system; MPH = methylphenidate.
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tial for further symptom reduction, try the next higher
dose. No further titration was permitted after the final
dose-adjustment visit at the end of week 3, and subjects
were maintained on their dose of MTS through the final
week. Subjects were followed up via phone call to caregiv-
ers at 30 ± 3 days after the last dose of study medication to
assess any new or ongoing AEs.
Health-related quality of life and medication satisfaction 
measures
As secondary objectives of this study, caregiver-reported
HRQL and medication satisfaction were assessed using
the ADHD Impact Module-Child (AIM-C) and a Medica-
tion Satisfaction Survey (MSS).
The AIM-C is a psychometrically sound and well-vali-
dated, disease-specific HRQL measure that includes mul-
tiple items and scales that assess the impact of ADHD
symptoms on children and their families [33]. Previous
psychometric data for the AIM-C instrument has indicated
excellent item convergent and discriminant validity as
well as very strong reliability with Cronbach  scores of
0.88 and 0.92 for the child and family subscales, respec-
tively. No floor effects and limited ceiling effects (2%)
were observed in a previous sample [33].
The AIM-C consists of 2 core scales to assess child (8
items) and family (10 items) HRQL. The measure also
consists of 2 multi-item scales to assess medication ten-
sion/worry (3 items regarding tension in administering
and taking ADHD medication) and missed-doses worry
(4 items regarding worry about the number of daily doses
missed at home or school). In addition, the AIM-C
includes 10 clinical treatment questions (including a
missed-dose item and 5 items that ask about behavioral
change and management), a 6-item school cooperation
scale, 9 parent attribute/knowledge items, 4 economic
impact items, and 4 demographic questions answered by
the subject's caregiver. Not all items and scales were uti-
lized in the study (refer to the Appendix 1). The AIM-C
was completed by the subject's caregiver at baseline and at
week 4.
The MSS is a nonvalidated 11-question survey designed to
assess caregiver satisfaction with the efficacy and tolerabil-
ity of MTS. The questions were answered by the subject's
caregiver at week 4. Responses ranged from "strongly
agree", "agree", "somewhat agree", "strongly disagree",
"disagree", and "somewhat disagree". For MSS data anal-
ysis, "strongly agree", "agree", and "somewhat agree" were
combined into the category "agreed". "Strongly disagree",
"disagree", and "somewhat disagree" were combined into
the category "disagreed".
Tolerability measures
Tolerability was based on spontaneous reports of AEs. Any
AEs were coded using the Medicinal Dictionary for Regula-
tory Activities (MedDRA) Version 7.0. Reported AEs were
monitored and recorded throughout the study and for 30
Table 1: MTS transition schedule and final dosages by ADHD medication at baseline
Baseline ADHD Medication Baseline Dose, mg/d Converted MTS Dose, mg/9 hour Final MTS Dose
Subjects, n (%)
10 mg
(n = 23)
15 mg
(n = 30)
20 mg
(n = 52)
30 mg
(n = 59)
Concerta®
(n = 112)
18 (n = 13) 10 5 (38.5) 5 (38.5) 3 (23.1) 0
27 (n = 24) 15 1 (4.2) 9 (37.5) 10 (41.7) 4 (16.7)
36 (n = 46) 20 0 1 (2.2) 26 (56.5) 19 (41.3)
45 (n = 2) 20 0 0 1 (50.0) 1 (50.0)
54 (n = 27) 30 0 0 1 (3.7) 26 (96.3)
Ritalin LA®
(n = 26)
10 (n = 3) 10 2 (66.7) 1 (33.3) 0 0
20 (n = 9) 10 4 (44.4) 3 (33.3) 2 (22.2) 0
30 (n = 9) 15 0 3 (33.3) 5 (55.6) 1 (11.1)
40 (n = 2) 20 0 1 (50.0) 0 1 (50.0)
50 (n = 3) 30 0 0 0 3 (100.0)
Metadate CD®
(n = 26)
10 (n = 1) 10 1 (100.0) 0 0 0
15 (n = 1) 10 1 (100.0) 0 0 0
20 (n = 12) 10 8 (66.7) 4 (33.3) 0 0
30 (n = 7) 15 1 (14.3) 3 (42.9) 1 (14.3) 2 (28.6)
40 (n = 3) 20 0 0 2 (66.7) 1 (33.3)
50 (n = 2) 30 0 0 1 (50.0) 1 (50.0)
MTS = methylphenidate transdermal system; ADHD = attention-deficit/hyperactivity disorder.Page 4 of 12
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rized AE intensity as "mild", "moderate", or "severe".
Tolerability has been briefly discussed herein to provide
context to those MSS items relating to the known side
effect of stimulant medications, including MTS, as rated
by caregivers.
Statistical analysis
Subjects who received at least 1 MTS patch application
and who had at least 1 ADHD-RS-IV measurement on or
after week 1 were included in the intent-to-treat (ITT)
population. Analyses of HRQL and MSS data were con-
ducted for the entire ITT population as well as the follow-
ing ITT population subgroups: prior treatment (Concerta,
Ritalin LA, and Metadate CD), age (6-9 year olds and 10-
12 year olds), and gender.
Scores for the AIM-C Child Impact Scale, Family Impact
Scale, Medication Tension/Worry Scale, and Missed-
Doses Worry Scale were computed separately by summing
the items within each scale and deriving an overall mean
score. The raw mean scores for all 4 scales were then trans-
formed on a 0-100 continuum, with higher scores indicat-
ing less negative impact or improved HRQL. Thus,
increasing AIM-C scores for these 4 scales is indicative of
improvement. The 5 AIM-C behavior items, the 1 missed-
dose item, and the 4 economic impact items were treated
as discrete categorical variables.
Summary statistics were presented for the 2 primary
HRQL AIM-C scales, Child and Family Impact, as absolute
change from baseline or number and percentage of sub-
jects experiencing outcomes. In the case of absolute
change from baseline, descriptive (number, mean, SD,
median, minimum, and maximum) statistics were com-
puted. Findings for the remaining secondary portions of
the AIM-C, including the 2 worry scales, 5 behavior items,
the missed-dose item, and the 4 economic impact items,
were briefly summarized using descriptive statistics.
Data for MSS were summarized as number and percentage
of subjects with the following responses to each of the sur-
vey questions using descriptive statistics: "strongly agree",
"agree", "somewhat agree", "strongly disagree", "disa-
gree", and "somewhat disagree".
The safety population was defined as all subjects who
received at least 1 MTS patch application. Safety-related
information was evaluated using descriptive statistics.
Adverse events were considered to be treatment emergent
if they began on or after the first patch application, or on
or before 30 days after the final patch application in this
study.
Results
Subjects
A total of 171 subjects were enrolled in the study. Subject
demographics and baseline characteristics are shown in
Table 2. All subjects received at least 1 MTS patch applica-
tion; therefore, all subjects were included in the safety
population. The ITT population was made up of 164 sub-
jects; each received at least 1 MTS patch and had at least 1
ADHD-RS-IV evaluation on or after week 1. Three subjects
were discontinued from the study due to AEs resulting in
150 subjects (87.7%) completing the 4-week study (Fig-
ure 2).
Health-related quality of life
AIM-C Child Impact Scale
Across all MTS doses, child HRQL scores had a tendency
to change for the better rather than to deteriorate. At base-
line, while subjects were receiving a stable dose of oral ER-
MPH, the AIM-C child HRQL mean (SD) score was 62.4
(20.5). At end of study, the child HRQL mean (SD) score
increased to 73.4 (18.4), reflective of a 17.5% increase
after 4 weeks of treatment with MTS.
Subgroup analyses conducted by prior treatment with
Concerta, Ritalin LA, and Metadate CD revealed that
changes in mean from baseline to the end of study in the
AIM-C child HRQL score were 10.3, 17.1, and 7.3, respec-
tively. Those subjects previously taking Ritalin LA experi-
Table 2: Subject demographics and baseline characteristics, ITT 
population
Characteristic, N = 164 Baseline Endpoint
Age, mean (SD), years 9.4 (1.9) -
Sex (%)
Boys, n 117 (71.3) -
Girls, n 47 (28.7) -
Race, n (%)
White 129 (78.7) -
African American 19 (11.6) -
Asian 1 (0.6) -
Native Hawaiian/
Other Pacific Islander
1 (0.6) -
American Indian/
Alaska Native
1 (0.6) -
Other 13 (7.9) -
Weight, mean (SD), lb 75.6 (26.0) -
Height, mean (SD), in 54.2 (5.2) -
ADHD-RS-IV Score (SD)
Total 14.1 (7.5) 9.9 (7.5)
Inattentive 7.9 (4.3) 6.4 (5.3)
Hyperactive/impulsive 6.2 (4.5) 4.4 (4.5)
AIM-C Child Impact Score (SD)a 62.4 (20.5) 73.4 (18.4)
AIM-C Family Impact Score (SD)a 68.2 (23.3) 78.4 (21.7)
aBased on 161 subjects
ITT = intent to treat; ADHD-RS-IV = ADHD-Rating Scale-IV; AIM-C 
= ADHD Impact Module-ChildPage 5 of 12
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HRQL scores from baseline to end of study.
Improvements in child HRQL from baseline to end of
study were also noted in both the 6- to 9-year-old and 10-
to 12-year-old age groups; however, changes in mean
AIM-C child HRQL scores from baseline were greater for
subjects aged 6-9 years (12.3) than those aged 10-12 years
(9.6). Gender analysis revealed a greater improvement in
mean scores on the child HRQL measure from baseline to
end of study for girls (14.9) compared with boys (9.4).
AIM-C Family Impact Scale
Average family HRQL improved from baseline to end of
study for all MTS dose groups. At baseline the family
HRQL score (mean [SD]) was 68.2 (23.3). Family HRQL
mean (SD) score at end of study was 78.4 (21.7), reflective
of a mean absolute change from baseline of 10.2 and a
mean percent improvement of 15.0% in family HRQL.
Subgroup analyses by prior treatment revealed similar
changes in mean from baseline scores for Concerta (9.7),
Ritalin LA (9.2), and Metadate CD (13.0). For subjects
aged 6-9 years, the change in mean family HRQL scores
from baseline to end of study (14.4) was more than dou-
ble that demonstrated by subjects aged 10-12 years (6.1),
reflective of a 23.5% improvement in family HRQL after 4
weeks of MTS treatment. Gender analysis revealed a
greater improvement in child HRQL mean scores from
baseline to end of study for girls (11.8) versus boys (9.5).
AIM-C behavior Items
AIM-C items regarding behavioral issues were generally
improved over the course of the study. From baseline to
endpoint, percentages of caregivers agreeing that their
child's behavior "stayed the same" (ie, did not fluctuate
throughout the day as before) increased (35.4-73.3%),
those agreeing that their child's behavior tended to be up
and down at different times throughout the day decreased
(64.0-24.8%), and those agreeing that their child's behav-
ior became more problematic at night decreased (68.3-
39.1%). At study endpoint the majority of caregivers
(85.1%) reported that handling changes in their child's
behavior was not very difficult or a little difficult, and
63.8% reported that they were "very often" or "fairly
often" successful in getting their child to focus or regain
self-control.
Subgroup analyses based on prior treatment, age, and
gender demonstrated similar trends in these AIM-C
behavioral items.
AIM-C overall worry scales
Overall improvements from baseline to endpoint were
seen in the Medication Tension/Worry Scale and School/
Missed-Doses Worry Scale. On the Medication Tension/
Worry Scale, the mean (SD) score at baseline was 68.0
(24.95). At endpoint, the mean (SD) score was 85.4
(17.4), indicative of a change in mean from baseline of
17.3 and a percent improvement from baseline of 25.4%.
Subgroup analyses revealed that improvement in mean
scores from baseline to endpoint with regard to the Med-
ication Tension/Worry Scale scores were similar for all
prior treatment groups (16.7 [Concerta], 16.3 [Ritalin
LA], and 20.8 [Metadate CD]) as well as for the 6- to 9-
year-old and 10- to 12-year-old age groups (19.0 and 15.8,
respectively). Gender analysis demonstrated greater
improvement from baseline to endpoint in Medication
Tension/Worry Scale scores for girls (22.3) compared with
boys (15.4).
On the School/Missed-Doses Worry Scale, the mean (SD)
score at baseline was 79.1 (17.8). At endpoint, the mean
(SD) score was 90.1 (14.1), reflecting a percent improve-
ment in mean scores from baseline of 13.9%. Subjects
that were receiving Metadate CD prior to MTS dose transi-
tion showed a greater improvement from baseline to end-
point in the School/Missed-Doses Worry Scale score
(15.4) compared with those that were receiving Concerta
(10.5) or Ritalin LA (8.7), and improvement for girls
(16.3) was nearly double the improvement noted for boys
Subject disposition flow chartFigure 2
Subject disposition flow chart.
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groups.
AIM-C missed-dose item
The percentage of subjects with missed doses was reduced
at study endpoint (23.6%) compared with baseline
(28.6%), indicating a slight improvement in compliance.
This trend was also noted for prior treatment, age, and
gender subgroups as well.
AIM-C economic items
Overall, there were improvements from baseline to end-
point in all economic impact items. From baseline to end-
point, the percentage of subjects missing school days
decreased from 14.9-7.5%. The percentage of subjects
requiring no extra hours of tutoring, nursing, home
healthcare, or other services increased from 60.2% at
baseline to 77.6% at endpoint. Furthermore, from base-
line to endpoint, the percentage of caregivers reporting no
missed days of work to manage ADHD-related issues
increased from 78.3-86.3%. The percentage of subjects
with emergency room visits related to their ADHD symp-
toms was unchanged between baseline and endpoint at
1.9%. Prior treatment, age, and gender subgroup analyses
for all AIM-C economic impact items revealed similar
results.
Medication Satisfaction Survey
Ratings on the MSS are displayed in Table 3. At study end-
point, 93.8% of caregivers were satisfied with their child's
use of study medication, and satisfaction levels were high
across all patch sizes. Caregiver satisfaction was high
regarding MTS administration frequency and ease of com-
pliance. At endpoint, 97.5%, 96.2%, and 97.5% of car-
egivers were satisfied with how many times a day their
child needed to take MTS, how easy it was for their child
to take MTS, and agreed that MTS doses were rarely
skipped or missed, respectively.
Caregiver satisfaction with the effect of MTS on behavioral
symptoms was high (93.8%), reflecting respondents' sat-
isfaction with their child's behavior while he or she
received the study medication. The majority of caregivers
(82.6%) reported improvements in their child's social
interactions since beginning the study medication, and
91.9% were satisfied with the efficacy of the study medi-
cation on their child's attention. The majority of caregiv-
ers (93.1%) indicated a high level of satisfaction with the
duration of effect of the study medication on their child's
ADHD symptoms.
Regarding medication satisfaction with tolerability of
MTS, at study endpoint the majority of caregivers (59.6%)
agreed that the study medication decreased their child's
appetite. The majority of caregivers (88.1%) disagreed
that the study medication made their child feel sleepy dur-
ing the day, but 34.8% of respondents agreed that MTS
treatment made it hard for their child to fall asleep at
night. The number of caregivers reporting concerns about
their child's falling asleep at night appeared to be dose
related: 5 (33.3%) for subjects receiving MTS 15 mg, 15
(37.5%) for subjects receiving MTS 20 mg, and 38
(34.8%) for subjects receiving MTS 30 mg.
Prior treatment, age, and gender subgroup analyses pro-
duced similar results for all 11 MSS items.
Tolerability
A total of 201 treatment-emergent AEs (TEAEs) were
reported by 97 subjects (57%) in the safety population
during the 4-week study. Most TEAEs (> 98%) were con-
sidered to be mild to moderate in intensity and the most
common included headache (5.1%), decreased appetite
(4.7%), insomnia (3.5%), and upper abdominal pain
(2.7%).
A total of 7 subjects discontinued the study due to intoler-
able effects. Four subjects withdrew from the study
because of reactions at the application site that ranged
from definite erythema with severe itching to normal
appearance at the patch application site with moderate
itching. None of these 4 subjects reported continuing AEs
at follow-up. Three subjects reported AEs that led to study
withdrawal. Two subjects reported 4 serious AEs that at
follow up were reported to have resolved. A 7-year-old
boy experienced "worsening of ADHD symptoms" and
"condition aggravated" after receiving MTS 10 mg for 1
day; both events were considered unrelated to study treat-
ment. A 12-year-old girl experienced "acute depression"
and "suicide attempt" while receiving MTS 30 mg for 16
days; both events were considered possibly related to
study treatment. The last subject, a 6-year-old girl, contin-
ued to experience anger/irritability after MTS study medi-
cation was discontinued.
No deaths were reported during the study. At follow-up,
no subject reported continuing AEs.
Discussion
Overall, AIM-C scores for child and family impact, behav-
ior, worry, missed dose, and economic impact had a ten-
dency to improve with all doses of MTS treatment from
baseline to endpoint. Such results are consistent with
other published reports of pharmacotherapy impact on
HRQL in children with ADHD [38-46]. Interestingly, at
baseline, while subjects were taking a stable dose of oral
ER-MPH, AIM-C child and family HRQL scores were
already above the median possible score. However, AIM-
C child and family HRQL scores were further increased at
endpoint after 4 weeks of treatment with MTS. ThesePage 7 of 12
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and the family living with ADHD can be observed after
switching from a stable dose of oral ER-MPH to MTS and
carefully titrating to an optimal MTS dose in a relatively
short treatment period. HRQL in both children and fami-
lies improved during this study, which is consistent with
behavioral reciprocation often observed in treatment
strategies. Although clinical intervention tends to stress
the importance of caregivers as change agents of the child,
in turn, children are reciprocally change agents of the car-
egiver and of family life in general.
Caregivers of children in the Ritalin LA subgroup, children
aged 6-9 years, and girls reported greater improvements
from baseline to endpoint in child HRQL when compared
to the other subgroups. Children aged 6-9 years and girls
experienced greater improvements from baseline to end-
point in family HRQL when compared with children aged
10-12 years and boys. Improvements seen in family
HRQL for the prior treatment subgroups (Concerta, Rita-
lin LA, and Metadate CD) were not very much different
from one another.
Behavior, as measured by the AIM-C, was also generally
improved over the course of the study. At baseline, most
caregivers indicated inconsistency in their child's behavior
across the day in contrast to endpoint where the majority
reported consistency in behavior. Further, at study end-
point the majority of caregivers reported that handling
changes in their child's behavior was "not very difficult"
or only "a little difficult" and that they were "very often"
or "fairly often" successful in getting their child to focus or
regain self-control. It may be inferred that improvements
in behavior and the ability of the caregiver to manage
their child's behavior after treatment with MTS may posi-
tively impact the HRQL for children with ADHD and their
families.
Overall improvements from baseline to endpoint were
seen in the Tension/Worry Scale and School/Missed-
Doses Worry Scale, with the latter possibly due to a slight
reduction in number of missed doses reported by caregiv-
ers at study endpoint. Improvement in compliance may
reflect increasing capacity to establish a routine of patch
administration with time, although noncompliance is
often underestimated in any clinical trial.
Improvements from baseline were also noted for the AIM-
C economic impact items. Although the majority of car-
egivers reported no missed school days due to ADHD
symptoms at both baseline and endpoint, the number of
children who missed 1 or more days of school was lower
at endpoint compared to baseline. In addition at end-
point, there was a decrease in the number of missed days
from work for caregivers and in the number of subjects
requiring extra hours for tutoring, nursing, and home
healthcare. The number of subject visits to the emergency
room due to ADHD remained relatively unchanged from
baseline to endpoint. Although an economic evaluation
was not performed, the improvements in HRQL observed
in children with ADHD coupled with the decreased direct
and indirect costs associated with the disorder may lead to
MTS being a cost-effective treatment option from a soci-
etal perspective.
Overall, MSS scores were high across all dose groups.
When asked to rate their overall satisfaction, caregivers
indicated that they were satisfied with MTS as a treatment
for their child's ADHD (ie, overall satisfaction, 93.8%; sat-
isfaction with ease of use, 96.2%; and satisfaction with
duration of effect, 93.1%). Similar percentages of caregiv-
ers were satisfied with the behavioral efficacy of MTS as
well. Consistent with the commonly reported TEAEs of
decreased appetite and insomnia, the majority of caregiv-
ers agreed that the medication caused their child to want
to eat less, and approximately one-third of caregivers
agreed that the medication made it hard for their child to
fall asleep at night. A recently published study evaluating
MTS wear times of 4 and 6 hours, instead of the 9-hour
wear time used in this study, suggests that some late day
side effects may be attenuated by early removal of the
patch [25].
Limitations
The current study was open-label, with no control group,
and was nonrandomized. The sample was restricted to
subjects who were previously taking a stable dose of oral
ER-MPH with ADHD symptoms that were within 1.5 SDs
above age/sex norms. Thus, these results may not be gen-
eralizable to subjects who were not taking a stable dose of
oral ER-MPH or who had either a poor or excellent
response to oral ER-MPH prior to switching to MTS.
Table 3: Caregiver MTS treatment satisfaction at endpoint, ITT 
population
MSS Summary Agreement, %a
N = 161
Satisfied with frequency of daily dosing 97.5
Satisfied with ease of use 96.2
Child rarely missing a dose 97.5
Satisfied with child's behavior 93.8
Improvement in child's social interactions 82.6
Satisfied with how child pays attention 91.9
Satisfied with duration of effect on symptoms 93.1
Overall satisfaction 93.8
a"Strongly agree", "agree", and "somewhat agree" were combined into 
the "agreed" category.
MTS = methylphenidate transdermal system; ITT = intent to treat, 
MSS = Medication Satisfaction Survey.Page 8 of 12
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stable dose of their previous oral ER-MPH. Motivation for
participation in this study may have been prompted by
low efficacy, high prevalence of AEs, or low HRQL with
subjects' previous medications. These motivations for
study participation may have contributed to a bias toward
HRQL improvement.
HRQL was assessed using the AIM-C, a validated car-
egiver-completed measure. As noted earlier, the AIM-C
consists of a 10-item scale to assess the impact of ADHD
on the caregiver and life at home. In addition, the car-
egiver is also asked to report on how well their child is
completing chores/homework, behaving in public, and
working to his or her potential. The AIM-C Child Impact
Scale also includes items such as how comfortable the
child seems with others, how well the child seems to get
along with others, and how well he or she handles every-
day hassles. Thus, caregiver ratings in these latter areas
(although still valid from a personal perspective) provide
a more indirect account of the everyday impact of ADHD
on the HRQL of the child.
During the study, management of subjects involved regu-
lar visits, dose adjustments, and careful attention to AEs.
This optimal management may also have had a role in
improving behavior, HRQL, and satisfaction.
Subjects who failed to respond to psychostimulants in the
past, and those with conduct disorder, were excluded
from the study. Therefore, the results of this study should
not be extrapolated to these patient populations.
The current study was of a relatively short duration and
was designed to evaluate subject response after abrupt
conversion from ER-MPH to the MTS dose specified by
the dose-transition schedule. Thus, the safety data pre-
sented herein should not be considered representative of
the long-term safety of MTS or the safety of MTS in treat-
ment-naïve children with ADHD. Also, although a prede-
fined dose-transition schedule was utilized in this current
study, because of differences in bioavailability between
products, MTS dose should be titrated based on individ-
ual response when patients are switched from oral ER-
MPH formulations.
Despite these limitations, the results of this study imply
that MTS may further improve child and family HRQL, as
well as behavior, medication worry, and economic impact
item scores, as measured by the AIM-C in subjects switch-
ing from a stable dose of oral ER-MPH over a short treat-
ment period. Furthermore, following the abrupt
conversion from oral ER-MPH to MTS, the majority of car-
egivers were highly satisfied with MTS as a treatment
option for their children with ADHD. Further studies eval-
uating the long-term impact of MTS on HRQL as well as
analysis of probable predictors of HRQL change and/or
satisfaction will be important in understanding what ele-
ments of stimulant treatment contribute most to improve-
ments in HRQL and satisfaction. These studies will
require additional controls on medication administra-
tion, including optimal dosing for the compared agents,
as well as the use of blinded evaluators, and a validated
medication satisfaction instrument.
Conclusion
This study demonstrates that MTS was well tolerated and,
when carefully titrated, may further improve child and
family HRQL, as well as behavioral, medication worry,
and economic impact item scores, as measured by the
AIM-C in subjects switching to MTS from a stable dose of
oral ER-MPH after a short treatment period. Furthermore,
following the abrupt conversion from oral ER-MPH to
MTS, the majority of caregivers were highly satisfied with
MTS as a treatment option for their children with ADHD.
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Appendix 1
ADHD Impact Module - Child (AIM-C)©
Item Content
Thinking about your child's ADHD during the past 2
weeks, how much does each statement describe your
child?
• My child did well following through with chores and
homework on his/her own
• My child seemed to get along with kids his/her agePage 9 of 12
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with ADHD has been generally positive
• My child was able to deal well with everyday hassles
and frustrations with friends and siblings
• My child behaved well in public places like stores/
restaurants
• My child seemed comfortable with how things are
going with friends and siblings
• My child worked to his/her potential
• My child adapted well to disruptions or unexpected
changes in his/her routine
In general, how closely do each of the following state-
ments describe life for you and your family?
• My child's ADHD has added stress to our home life
• My child's ADHD limits me from entertaining at
home
• I avoid going certain places or doing certain things
with my child because of problems with his/her
ADHD
• I feel as if I am "on guard" in public settings because
I never know if my child with ADHD will act up
• My child's ADHD limits what we can do as a family
• I am anxious about my child's future because of the
ADHD problems he/she is having
• I feel tired and worn out because caring for a child
with ADHD requires a lot of my time and energy
• I feel my child's ADHD controls my life
• I am frustrated that my child's ADHD is unmanage-
able
• I am concerned about the long-term effect my child's
ADHD behavior may have on his/her siblings
Please tell us how long your child has been on the follow-
ing treatments for his/her ADHD.
*(NOTE: not used in the current study but part of the
AIM-C)
Which of the following statements best describes your
child's current ADHD medication status?
* *(NOTE: not used in the current study but part of the
AIM-C)
Are the following statements TRUE or FALSE for your
child?
• My child's behavior stays about the same throughout
the day
• My child's behavior seems to be up and down at dif-
ferent times throughout the day
• My child's behavior becomes more problematic at
night
• Is it difficult to handle changes in your child's behav-
ior when the medication wears off?
In general, how often are you successful in getting him/
her to focus or regain self-control?
How would you rate the school's cooperation in each of
the following areas?*
*(NOTE: this scale was not used in current study but is
part of the AIM-C)
• Diagnostic/testing process for ADHD
• Obtaining additional academic services
• Developing a classroom behavior management plan
• Designing a homework "plan of action"
• Giving your child his/her ADHD medicine
• Ongoing support in managing your child's ADHD
Please answer each of the following questions:
• How much tension is there between you and your
child about taking his/her ADHD medication?
• How much do you worry about your child missing a
dose of ADHD medication at school or when you are
not around?
• How bothered are you by having to monitor your
child's ADHD medication everyday?Page 10 of 12
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taking ADHD medication at school?
• How much does your child resist taking medication
at school?
• How often does your child's dose at school get
missed or forgotten?
• How often has your child had problems because of
a missed dose at school?
During the last 7 days, how many scheduled doses of your
child's ADHD medication have been missed?
How strongly do you agree or disagree with the following
statements?*
*(NOTE: Not used on this study but included in the AIM-
C)
• ADHD can be helped by drugs alone
• ADHD can be helped by behavioral interventions
and therapy/counseling WITHOUT medication
• ADHD can be helped by behavioral interventions
and therapy/counseling with medication
• ADHD can't really be helped. It's something my
child will "outgrow"
During the past 6 months, has your child missed days
from school due to problems with his/her ADHD?
During the past 6 months, have you, your spouse or part-
ner missed days from work due to problems with your
child's ADHD?
During the past 6 months, has your child required any
hours of extra tutoring, nursing, home healthcare, or
other services as a result of his/her ADHD?
During the past 6 months, has your child visited an emer-
gency room due to an accident or incident that you
believe was related to his/her ADHD?
[Reproduced with permission from HealthActCHQ Inc.©
Copyright 2006-2008. All rights reserved.]
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